Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
PHERFLOT
Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma
- NCT05504720 ↗
- Completed
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Standard
We haven't built an HCP commentary report on PHERFLOT (pembrolizumab, trastuzumab and 1 more in Esophagogastric Adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PHERFLOT so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 10 | |
| YouTube | 3 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- Pembrolizumab and Trastuzumab in Combination With FLOT in the Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma - A Phase II Trial of the AIO Study Group - PHERFLOT -
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Esophagogastric Adenocarcinoma
- Interventions
- Pembrolizumab; Trastuzumab; FLOT
- Arms
- Pembrolizumab Trastuzumab · Experimental
- Enrollment
- 31
- Primary outcomes
- Disease-free survival after 2 years co-primary endpoint
- Pathological complete response rate co-primary endpoint
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest with Merck Sharp & Dohme LLC, Organon Healthcare GmbH
- Start
- Feb 13, 2023
- Primary completion
- Jul 15, 2026
- Results posted
- No
- Registry record
- NCT05504720 · updated Aug 10, 2026
Publications
linked from the registry- Stein A, Goekkurt E, Al-Batran SE, Moosmann N, Ettrich TJ, Goetze T, Gruen B, Homann N, Lorenzen S, Hofheinz RD, Rempel V, Siegler G, Muller C, Thiele B, Broering T, Cruz MS, Pauligk C, Binder M, Tintelnot J. Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial. Nat Med. 2025 Dec;31(12):4197-4204. doi: 10.1038/s41591-025-03979-y. Epub 2025 Oct 18. PubMed 41109919
- Tintelnot J, Stein A, Al-Batran SE, Ettrich T, Gotze T, Grun B, Haag GM, Heuer V, Hofheinz RD, Homann N, Broring TS, Cruz MS, Kurreck A, Lorenzen S, Moosmann N, Muller C, Schuler M, Siegler G, Binder M, Gokkurt E. Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321). Front Oncol. 2023 Oct 16;13:1272175. doi: 10.3389/fonc.2023.1272175. eCollection 2023. PubMed 37909020